Idexx Laboratories reports Q1 EPS $2.55, consensus $2.42

Reports Q1 revenue $900M, consensus $892.88M. "Strong execution by IDEXX commercial and operational teams drove excellent growth results and financial performance in the first quarter," said CEO Jay Mazelsky. "Commercial engagement and IDEXX innovations are supporting our customers as they work to address growing demand for pet healthcare. IDEXX’s ongoing focus on addressing the needs of veterinary clinics is aligned with developing the long-term global growth opportunity for companion animal diagnostics."